Recursion Pharmaceuticals, Inc. operates at the intersection of technology and biology, leveraging its AI-native platform to discover and develop new medicines. The company's business model spans advancing a wholly-owned internal pipeline of clinical-stage candidates—targeting conditions such as cerebral cavernous malformation and familial adenomatous polyposis—and forming strategic partnerships with major pharmaceutical companies. By combining high-throughput automated cellular imaging with advanced machine learning, Recursion generates massive proprietary datasets to predict drug-disease relationships and optimize molecular design. Headquartered in Salt Lake City, Utah, the company has expanded its capabilities through strategic acquisitions in the AI drug discovery space, including Exscientia and Cyclica. Recursion's competitive position is defined by its infrastructure that scales biological experimentation to support both internal therapeutic development and external collaborative programs.
